3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Cisplatin
109
Radiotherapy
100
Fluorouracil
90
Paclitaxel
75
Oxaliplatin
63
Docetaxel
56
Carboplatin
55
Irinotecan
41
Esophagectomy
41
Leucovorin
40
Capecitabine
39
Surgical Procedures, Operative
36
Radiation
36
Drug Therapy
31
Neoadjuvant Therapy
25
Chemoradiotherapy
18
Cetuximab
18
S 1 (combination)
17
pembrolizumab
16
camrelizumab
16
Nivolumab
15
Magnetic Resonance Spectroscopy
15
Bevacizumab
15
Blood Specimen Collection
14
Surveys and Questionnaires
12
Radiotherapy, Intensity-Modulated
12
Immunotherapy
11
Epirubicin
11
Biopsy
11
Trastuzumab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled